Gemcitabine plus folfox 4 (GOLF) followed by subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) in colon carcinoma patients in second/third line of treatment. An update from the multicenter GOLFIG-1 phase II trial

被引：0
|
作者：
Correale, P.
Remondo, C.
Intrivici, C.
Montagnani, F.
Marsili, S.
La Placa, M.
Pascucci, A.
Sciandivasci, A.
Paolelli, L.
Rotundo, M. Saveria
Tagliaferri, P.
Tassone, P.
Venuta, S.
Francini, G.
机构：
[1] Univ Siena, Sch Med, Dept Human Pathol & Oncol, I-53100 Siena, Italy
[2] Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Sect Oncol, Catanzaro, Italy
[3] Univ Palermo, Operat Unit Med Oncol, Palermo, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：VII148 / VII148
页数：1
相关论文
共 23 条
  • [1] Chemo-immunotherapy regimen with gemcitabine plus FOLFOX 4 (GOLF) followed by subcutaneous (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). Results from a multicenter phase II trial in colon carcinoma patients.
    Correale, P.
    Remondo, C.
    Montagnani, F.
    Rotundo, M. S.
    Marsili, S.
    Laplaca, M.
    Tassone, P.
    Tagliaferri, P.
    Venuta, S.
    Francini, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 167S - 167S
  • [2] Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine plus FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 trial)
    Correale, Pierpaolo
    Tagliaferri, Pierosandro
    Fioravanti, Antonella
    Del Vecchio, Maria Teresa
    Remondo, Cinzia
    Montagnani, Francesco
    Rotundo, Maria Saveria
    Ginanneschi, Chiara
    Martellucci, Ignazio
    Francini, Edoardo
    Cusi, Maria Grazia
    Tassone, Pierfrancesco
    Francini, Guido
    CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4192 - 4199
  • [3] Phase II study of thalidomide, interleukin-2 (IL-2) plus granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (MRCC).
    Amato, R
    Rawat, A
    Attumi, T
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8977S - 8977S
  • [4] GROWTH OF AN INTERLEUKIN-2 INTERLEUKIN 4-DEPENDENT T-CELL LINE INDUCED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)
    KUPPER, T
    FLOOD, P
    COLEMAN, D
    HOROWITZ, M
    JOURNAL OF IMMUNOLOGY, 1987, 138 (12): : 4288 - 4292
  • [5] Phase II Study of thalidomide, Interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC).
    Rawat, A
    Arnato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 431S - 431S
  • [6] Granulocyte-macrophage colony stimulating factor (GM-CSF) & interleukin-2 (IL-2) combination as adjuvant therapy in cutaneous melanoma. Early results of a phase II clinical trial.
    Elias, EG
    Zapas, JL
    Beam, SL
    Brown, SD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 724S - 724S
  • [7] Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma
    Garcia, Jorge A.
    Mekhail, Tarek
    Elson, Paul
    Wood, Laura
    Bukowski, Ronald M.
    Dreicer, Robert
    Rini, Brian I.
    BJU INTERNATIONAL, 2012, 109 (01) : 63 - 69
  • [8] Cancer gene therapy treatment using adenoviral thymidine kinase (TK)/ganciclovir (GCV) plus adeno granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin-2 (IL-2) immunotherapy
    Chiang, YH
    CANCER GENE THERAPY, 1999, 6 (06) : S19 - S19
  • [9] Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients
    Correale, P
    Cusi, MG
    Tsang, KY
    Del Vecchio, MT
    Marsili, S
    La Placa, M
    Intrivici, C
    Aquino, A
    Micheli, L
    Nencini, C
    Ferrari, F
    Giorgi, G
    Bonmassar, E
    Francini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (35) : 8950 - 8958
  • [10] Gene therapy of the CT26 tumor model with the manipulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) by a tetracycline-inducible system
    Lee, SG
    Jee, YS
    Park, SY
    Yoon, SJ
    Kang, JO
    Kim, CD
    Rhee, CS
    Sung, MW
    Heo, DS
    Kim, NK
    CANCER GENE THERAPY, 1999, 6 (06) : S28 - S29
123